Advanced search
Publication Cover
Leukemia & Lymphoma Volume 60, 2019 - Issue 8
Submit an article Journal homepage
252
Views
11
CrossRef citations to date
0
Altmetric
Letter to the Editor

Bortezomib-based regimens in patients with POEMS syndrome: a case series in newly diagnosed and relapsed patients

Marcello RivaHaematology and Clinical Immunology Unit, Department of Medicine, University of PadovaPadova, Italy; ORCID Iconhttp://orcid.org/0000-0002-0125-9036
ORCID Icon,
Federica LessiHaematology and Clinical Immunology Unit, Department of Medicine, University of PadovaPadova, Italy; Correspondence[email protected]
,
Tamara BernoHaematology and Clinical Immunology Unit, Department of Medicine, University of PadovaPadova, Italy;
,
Andrea VisentinHaematology and Clinical Immunology Unit, Department of Medicine, University of PadovaPadova, Italy;
,
Marta CampagnoloNeurology Unit, Department of Neuroscience, University of Padova, Padova, Italy
,
Gianpietro SemenzatoHaematology and Clinical Immunology Unit, Department of Medicine, University of PadovaPadova, Italy;
,
Fausto AdamiHaematology and Clinical Immunology Unit, Department of Medicine, University of PadovaPadova, Italy;
&
Chiara BrianiNeurology Unit, Department of Neuroscience, University of Padova, Padova, Italy
 show all
Pages 2067-2070 | Received 25 Sep 2018, Accepted 23 Dec 2018, Published online: 22 Jan 2019

References

  • Nozza A, Terenghi F, Gallia F, et al. Lenalidomide and dexamethasone in patients with POEMS syndrome: results of a prospective, open-label trial. Br J Haematol. 2017;179:748–755.
  • Warsame R, Kohut Ingrid E, Dispenzieri A. Successful use of cyclophosphamide, bortezomib, and dexamethasone to treat a case of relapsed POEMS. Eur J Haematol. 2012;88:549–550.
  • He H, Fu W, Du J, et al. Successful treatment of newly diagnosed POEMS syndrome with reduced-dose bortezomib based regimen. Br J Haematol. 2018;181:126–128.
  • Dispenzieri A. POEMS syndrome: 2017 update on diagnosis, risk stratification, and management. Am J Hematol. 2017;92:814–829.
  • Cavaletti G, Frigeni B, Lanzani F, et al. The Total Neuropathy Score as an assessment tool for grading the course of chemotherapy-induced peripheral neurotoxicity: comparison with the National Cancer Institute-Common Toxicity Scale. J Peripher Nerv Syst. 2007;12:210–215.
  • Dimopoulos MA, Mateos MV, Richardson PG, et al. Risk factors for, and reversibility of, peripheral neuropathy associated with bortezomib-melphalan-prednisone in newly diagnosed patients with multiple myeloma: subanalysis of the phase 3 VISTA study. Eur J Haematol. 2011;86:23–31.
  • Mu SD, Ai LS, Qin Y, et al. Subcutaneous versus intravenous bortezomib administration for multiple myeloma patients: a meta-analysis. Curr Med Sci. 2018;38:43–50.
  • Pitarokoili K, Yoon MS, Kroger I, et al. Severe refractory CIDP: a case series of 10 patients treated with bortezomib. J Neurol. 2017;264:2010–2020.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.